CalciMedica, Inc. CALC
Regular-session close
After hours · Nov 19, 7:58 PM ET
- YTD
- -96.45%
- 1 year
- -92.59%
5D -0.16 (-11.59%)
- Market cap
- 8.07M
- EPS (ttm)
- -4.41
- Shares out
- 13.48M
- Forward P/E
- -1.69
- YTD return
- -96.45%
- 1-year return
- -92.59%
- 50-day average
- 3.46
- Volume
- 118.15K
- Avg volume
- 81.34K
- Open
- 1.13
- Previous close
- 1.17
- Day's range
- 1.12 – 1.22
- 52-week range
- 1.00 – 36.00
- Price target
- 17.00 (+1353.0%)
Key statistics
- 200-day average
- 4.33
- Enterprise value
- 17.09M
- Price / book
- 1.95
- Free cash flow
- -12.45M
- Total cash
- 19.14M
- Return on equity
- -83.76%
- Short % of float
- 1.25%
Fundamental scorecard
5 of 25 checks passed on CALC’s reported financials
5of 25 checks passed
- Value 1 of 5
- Growth 1 of 5
- Profitability 0 of 5
- Financial health 3 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 13, 2024 | Sep 1, 2024 | -0.61 | -0.50 | +0.11 | +18.03% |
| Aug 12, 2024 | Jun 1, 2024 | -0.55 | -0.52 | +0.03 | +5.45% |
| Aug 12, 2024 | Jun 1, 2024 | -0.55 | — | — | — |
| May 13, 2024 | Mar 1, 2024 | -0.50 | — | — | — |
| May 13, 2024 | Mar 1, 2024 | -0.50 | -0.43 | +0.07 | +14.00% |
| Mar 28, 2024 | Dec 1, 2023 | -1.00 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 17, 2024 | LUCID CAPITAL MARKETS | init | — | Buy |
| Nov 14, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Nov 4, 2024 | HC Wainwright & Co. | main | Buy | Buy |
| Aug 13, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Jul 10, 2024 | Oppenheimer | main | Outperform | Outperform |
| Jul 9, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
About CalciMedica, Inc.
CalciMedica, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia. It also develops CM6336, an oral CRAC channel inhibitors for chronic inflammatory indications; and Auxora, for the treatment of acute ulcerative colitis and allergic asthma. The company is based in La Jolla, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- calcimedica.com
News
12 Health Care Stocks Moving In Friday's Pre-Market Session
What Makes CalciMedica Inc. (CALC) a New Buy Stock CalciMedica Q3 EPS $(0.24) Beats $(1.27) Estimate
CalciMedica Reports Third Quarter 2026 Financial Results and Provides Clinical & Corporate Updates
CalciMedica to Participate in the Guggenheim 3rd Annual Healthcare Innovation Conference
12 Health Care Stocks Moving In Monday's Pre-Market Session
Why Inovio Pharmaceuticals Shares Are Trading Higher By Over 230%; Here Are 20 Stocks Moving Premarket
12 Health Care Stocks Moving In Friday's After-Market Session
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
CalciMedica Inc. (NASDAQ:CALC) Stock Has Average Price Target of $50.00 According to Analysts
Your note
Sign in to keep a note on CALC — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BJERKHOLT ERIC H | Director | Purchase | May 30, 2023 | 3,684 |
| DUNN MICHAEL JOHN | President | Conversion of Exercise of derivative security | Sep 8, 2024 | 11,761 |
| HEBBAR SUDARSHAN | Officer | Purchase | Nov 2, 2023 | 46,000 |
| LEHENY A RACHEL | Chief Executive Officer | Purchase | Oct 31, 2024 | 871,252 |
| MIDDLETON FRED A | Director and Beneficial Owner of more than 10% of a Class of Security | Purchase | Dec 5, 2024 | 2,451,860 |
| ROBERTS ERIC W | Officer, Director and Beneficial Owner | Purchase | Oct 31, 2024 | 974,810 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Deerfield Management Company, L.P. (Series C) | 17.66% | 1,000,000 | 2.76M | Sep 29, 2024 |
| Soleus Capital Management, L.P. | 13.85% | 783,904 | 2.16M | Sep 29, 2024 |
| Aisling Capital Management LP | 9.20% | 521,114 | 1.44M | Sep 29, 2024 |
| Vanguard Group Inc | 4.49% | 254,148 | 701.45K | Sep 29, 2024 |
| BML Capital Management, LLC | 2.72% | 153,887 | 424.73K | Sep 29, 2024 |
| Geode Capital Management, LLC | 1.18% | 66,553 | 183.69K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 3.99% | 226,183 | 624.26K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.59% | 33,310 | 91.94K | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 0.49% | 27,965 | 77.18K | Sep 29, 2024 |
| iShares Micro Cap ETF | 0.26% | 14,545 | 40.14K | Oct 30, 2024 |
| Fidelity Total Market Index Fund | 0.21% | 11,756 | 32.45K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.14% | 8,038 | 22.18K | Oct 30, 2024 |
